Dr. Breelyn Wilky provided an informative session about the role of the immune system in GIST and implications for future therapies to attendees at The March 25th Miami GDOL. GDOLs are free one-day [...]
Lisa Marie Merheb, from the Sylvester Cancer Center in Miami, enlightened attendees with a session on support and direction as she spoke about Psychosocial implications at The March 25th Miami GDOL. GDOLs are [...]
Sosipatros Boikos, MD from Massey Cancer Center in Richmond, Virginia spoke about advances and challenges in KIT/PDGRFA Wild Type GIST and implications for treatment. GDOLs are free-one day programs that provide both education and [...]
The latest edition of the GIST and Sarcoma Journal is now available online. The GIST and Sarcoma Journal is a comprehensive and authoritative resource for scientifically valid information for physicians, allied healthcare professionals [...]
The Life Raft Group is pleased to announce a new collaboration to provide access to our valuable resource tool, SideEQ, to the LeioMyoSarcoma Patient-Family-Care Partner Community. Commencing on May 5, members of [...]
The Life Raft Group presented an informative webcast on Fertility, Pregnancy and GIST. Presented on March 30, 2017 Learn about: Impact of cancer treatment on fertility Options to preserve eggs and sperm [...]
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
The Life Raft Group presented an informative webcast on Gene Fusions. Presented on February 22, 2017 Learn about: Recently identified gene fusions in GIST Populations they target Current studies that may identify them How they [...]
The Life Raft Group Patient Registry has over 15 years of self-reported and clinical data encompassing 35 years of patient history crossing institutional boundaries. The Patient Registry has 1703 patients from 67 countries, [...]
This article originally appeared in the January 30th edition of Cure Today. Less than two decades ago, Gleevec (imatinib) drastically changed the frontline treatment for patients with gastrointestinal stromal tumors (GIST). However, as patients [...]
